The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
Launched by SHENYANG NORTHERN HOSPITAL · Jul 2, 2018
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age between 18-75
- • 2. Patients with complexity of CAD determined by coronary angiography and implanted stent successfully
- • 3. Taking clopidogrel 75mg daily over 5 days or paients never took clopidogrel previously should receive 300-600mg drugs at least 12 hours before coronary angiography
- • 4. Agreeing to participate in this trial and signed the written informed consent.
- Exclusion Criteria:
- • 1. They contraindicated with ticagrelor (including: allergying to ticagrelor or its active metabolite
- • 2. Concomitanting therapy with a strong cytochrome P-450 3A inhibitor or inducer
- • 3. Previous intracranial haemorrhage or ongoing bleeds
- • 4. Moderate or severe hepatic impairment)
- • 5. Having a previous medication with ticagrelor or long term anticoagulation
- • 6. Having a history of asthma or chronic obstructive pulmonary disease (COPD) and recurrent attacked
- • 7. Having an uncontrolled hypertension\>180/110mmHg
- • 8. Having a hemoglobin\<100g/L 9.Having a platelet counts\<100×10\^9/L
- • 9. Having severe renal impairment (clearance\<30mL/min)
- • 10. Having a history of hepaein-induced thrombocytopenia (HIT)
- • 11. Having a pregnancy or were during lactation.
About Shenyang Northern Hospital
Shenyang Northern Hospital is a leading healthcare institution based in Shenyang, China, renowned for its commitment to advancing medical research and patient care. As a clinical trial sponsor, the hospital focuses on innovative therapeutic solutions and strives to enhance treatment outcomes across various medical fields. With a dedicated team of experienced researchers and clinicians, Shenyang Northern Hospital emphasizes rigorous ethical standards and scientific integrity in its trials. The institution is equipped with state-of-the-art facilities and a diverse patient population, enabling it to contribute significantly to the global medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenyang, Liaoning, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials